P38 Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial -Endorphin Expression
Introduced by Novo Nordisk in 2026, oral semaglutide became the first oral GLP-1 specifically approved for weight loss, distinguishing it from Rybelsus, which targets type 2 diabetes
Managing reactions during dose changes and medication switches Dose escalation and medication transitions are the two highest-risk periods for injection site reactions outside of initial treatment
Focusing on certain foods and lifestyle changes may help you manage these side effects
Awareness is up since July 2023, when about one in five (19%) said they heard a lot about the drugs. About eight in ten (79%) adults who have taken GLP-1 drugs report getting these drugs or a prescription for them from their primary care doctor or a specialist
Semaglutide Benefits Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been making waves in the world of weight management due to its impressive ability to promote weight loss